ADD TO THE AGENDA | FALL 2022

TPA’S ANNUAL GALA

We are thrilled that The Pink Agenda’s Annual Gala is back in person this year at Tribeca Rooftop! We hope you can join us on Thursday, October 6 at 7:30 PM to party for a purpose and raise money, raise awareness, and raise hell for lifesaving breast cancer research.

Click here to purchase tickets and sponsorships now! 

TPA’S ATLANTA GALA

Join us at The College Football Hall of Fame for The Pink Agenda’s Annual Atlanta Gala on Thursday, October 20 at 7:00 PM! Enjoy an evening of fun, philanthropy, and celebration with great food, music, and a fabulous silent auction!

Don’t wait – click here to buy tickets and sponsorships today!

---

SUMMER RECAP

The Pink Agenda kept busy this summer with some wonderful events in New York, Boston, and Atlanta! Thank you to all our supporters who were able to attend as well as to Yankee Stadium, Night Shift Brewing, and Barre3 Buckhead for having us!

Check out all our upcoming events thepinkagenda.org/events!

TPA TALKS

The Pink Agenda held its annual health and wellness educational symposium, TPA Talks Live, on Thursday, June 9, at The Sheen Center for Thought & Culture. The presenters covered a wide range of topics–– from philanthropy to survivorship to the latest breakthroughs in breast cancer research–– to engage and educate audience members.

Tune in to the final installment of this educational series, TPA Talks: On the Agenda | Understanding the Risks of Breast Cancer on Thursday, November 10, streaming live virtually at 6:30 PM ET. Click here to purchase tickets today!

RESEARCH UPDATES

JOSHUA SALDIVAR, PhD
Dr. Joshua Saldivar has discovered a novel link between an enzyme named ATR and a protein complex called Mediator. Mediator helps determine a cell’s identity, including cancer stem cells, and ATR is likely an important driver of cancer stem cell formation through its link to Mediator. By deepening our understanding of how cancer stem cells emerge, novel strategies can be developed to stop cancer in its earliest stages.

ANN PARTRIDGE, MD, MPH
Dr. Ann Partridge and her team expanded their work into several additional studies, including an intervention program, Young Empowered and Strong (YES). Her team designed and launched YES as an internet-based portal that not only follows and supports patients virtually over time but navigates them to relevant education and supportive care resources. This work recently received additional funding from the National Institutes of Health so that it can be expanded into a randomized controlled trial.

JOSHUA SALDIVAR, PhD
Dr. Joshua Saldivar has discovered a novel link between an enzyme named ATR and a protein complex called Mediator. Mediator helps determine a cell’s identity, including cancer stem cells, and ATR is likely an important driver of cancer stem cell formation through its link to Mediator. By deepening our understanding of how cancer stem cells emerge, novel strategies can be developed to stop cancer in its earliest stages.

ADRIENNE WAKS, MD
Dr. Adrienne Waks has two studies underway: one is analyzing the data from a recently completed clinical trial, DAPHNe that used two different HER2 antibodies, and the other, MARGOT, is a clinical trial with a new type of HER2 antibody. In the DAPHNe trial, the team found significant differences in immune cells between pre-treatment tumors that are hormone receptor-positive versus hormone receptor-negative, which could affect how those tumors respond to antibody therapies.

To learn more about our impact and the current research projects we are funding, visit thepinkagenda.org/impact today.

NYC MARATHON

The Pink Agenda is proud to be an official charity partner of the 2022 TCS New York City Marathon. Our marathon runners have raised over $80,000 so far this year and over $1 million in total for breast cancer research! Running 26.2 miles isn’t easy, but neither is undergoing breast cancer treatment or eradicating the disease.

Click here to support our 2022 TCS NYC Marathon team! More details to follow on the location of this year’s cheer section.